Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2Breast 2

Conditions

Breast Neoplasms 10180Triple Negative Breast Neoplasms 1045Neoplasms 573Ovarian Neoplasms 564Neoplasm Metastasis 515Colorectal Neoplasms 472Carcinoma, Non-Small-Cell Lung 467Prostatic Neoplasms 440Lung Neoplasms 433Pancreatic Neoplasms 312Melanoma 299Stomach Neoplasms 295Breast Neoplasms, Male 257Motor Activity 252Colonic Neoplasms 238Uterine Cervical Neoplasms 227Endometrial Neoplasms 223Head and Neck Neoplasms 218Carcinoma, Intraductal, Noninfiltrating 217Carcinoma, Renal Cell 192Squamous Cell Carcinoma of Head and Neck 181Sarcoma 176Urinary Bladder Neoplasms 159Esophageal Neoplasms 155Brain Neoplasms 155Breast Carcinoma In Situ 154Lymphedema 148Fatigue 136Carcinoma, Ovarian Epithelial 134Small Cell Lung Carcinoma 130

Interventions

trifluridine tipiracil drug combination 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Advanced Solid Tumors (Excluding Breast Cancer) × Breast × Clear all
NCT01867879 2024-09-05

Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors

Taiho Oncology, Inc.

Phase 1 Completed
44 enrolled
BreastOther solid neoplasm

Advanced Solid Tumors (Excluding Breast Cancer)

NCT01874522 2024-09-05

Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI

Taiho Oncology, Inc.

Phase 1 Completed
46 enrolled
BreastOther solid neoplasm

Advanced Solid Tumors (Excluding Breast Cancer)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡